- Home
- QGEN vs PEN Comparison
QGEN vs PEN Comparison
Compare QGEN & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QGEN
- PEN
- Stock Information
- Founded
- QGEN 1986
- PEN 2004
- Country
- QGEN Netherlands
- PEN United States
- Employees
- QGEN N/A
- PEN N/A
- Industry
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PEN Medical/Dental Instruments
- Sector
- QGEN Health Care
- PEN Health Care
- Exchange
- QGEN Nasdaq
- PEN Nasdaq
- Market Cap
- QGEN 9.9B
- PEN 11.1B
- IPO Year
- QGEN 1996
- PEN 2015
- Fundamental
- Price
- QGEN $40.16
- PEN $267.21
- Analyst Decision
- QGEN Buy
- PEN Strong Buy
- Analyst Count
- QGEN 8
- PEN 16
- Target Price
- QGEN $49.79
- PEN $291.60
- AVG Volume (30 Days)
- QGEN 1.1M
- PEN 412.9K
- Earning Date
- QGEN 04-28-2025
- PEN 05-06-2025
- Dividend Yield
- QGEN 3.31%
- PEN N/A
- EPS Growth
- QGEN N/A
- PEN N/A
- EPS
- QGEN 0.37
- PEN 0.36
- Revenue
- QGEN $1,978,214,000.00
- PEN $1,194,615,000.00
- Revenue This Year
- QGEN $5.15
- PEN $14.26
- Revenue Next Year
- QGEN $6.49
- PEN $14.29
- P/E Ratio
- QGEN $107.70
- PEN $742.64
- Revenue Growth
- QGEN 0.66
- PEN 12.86
- 52 Week Low
- QGEN $37.63
- PEN $148.00
- 52 Week High
- QGEN $47.93
- PEN $310.00
- Technical
- Relative Strength Index (RSI)
- QGEN 53.09
- PEN 43.99
- Support Level
- QGEN $39.35
- PEN $273.00
- Resistance Level
- QGEN $40.11
- PEN $288.57
- Average True Range (ATR)
- QGEN 0.53
- PEN 8.17
- MACD
- QGEN 0.20
- PEN -1.26
- Stochastic Oscillator
- QGEN 92.43
- PEN 33.31
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.